OSIRIS, NCT04737382: Osimertinib Resistance in Patients With Non-small-cell Lung Carcinoma That Have Progressed. |
|
|
| Recruiting | N/A | 200 | Europe | biopsy, ctDAN analysis | The Netherlands Cancer Institute, AstraZeneca | Non-small-cell Lung Carcinoma | 08/24 | 08/24 | | |
| Not yet recruiting | N/A | 110 | Europe | Standard-dose intensity-modulated proton therapy (IMPT-60), Dose-escalated intensity-modulated proton therapy (IMPT-74), Cisplatin or carboplatin + pemetrexed for induction chemotherapy, cisplatin + docetaxel for concurrent chemotherapy, Immunotherapy: adjuvant durvalumab | University Medical Center Groningen, Dutch Cancer Society | Carcinoma, Non-Small-Cell Lung | 01/26 | 01/27 | | |
